

2 February 2023

**Notice under section 708A(5)(e) of the Corporations Act 2001  
Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)**

Reference is made to the Appendix 2A released on 2 February 2023 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (“Shares”). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- (a) The Company issued Shares upon the exercise of unlisted Share Options as follows:

<b>Date of issue</b>	<b>Shares issued</b>	<b>Options exercised</b>
19/01/2023	168,352	168,352
20/01/2023	270,672	350,000
30/01/2023	240,751	328,556
<b>Total</b>	<b>679,775</b>	<b>846,908</b>

- (b) The Company issued the shares without disclosure under part 6D.2 of the Corporations Act;
- (c) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act; and
- (d) As at the date of this notice there is no information which is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by



Genevieve Ryan  
Company Secretary